[18F]fallypride-PET/CT Analysis of the Dopamine D2/D3 Receptor in the Hemiparkinsonian Rat Brain Following Intrastriatal Botulinum Neurotoxin A Injection

Intrastriatal injection of botulinum neurotoxin A (BoNT-A) results in improved motor behavior of hemiparkinsonian (hemi-PD) rats, an animal model for Parkinson’s disease. The caudate–putamen (CPu), as the main input nucleus of the basal ganglia loop, is fundamentally involved in motor function and directly interacts with the dopaminergic system. To determine receptor-mediated explanations for the BoNT-A effect, we analyzed the dopamine D2/D3 receptor (D2/D3R) in the CPu of 6-hydroxydopamine (6-OHDA)-induced hemi-PD rats by [18F]fallypride-PET/CT scans one, three, and six months post-BoNT-A or -sham-BoNT-A injection. Male Wistar rats were assigned to three different groups: controls, sham-injected hemi-PD rats, and BoNT-A-injected hemi-PD rats. Disease-specific motor impairment was verified by apomorphine and amphetamine rotation testing. Animal-specific magnetic resonance imaging was performed for co-registration and anatomical reference. PET quantification was achieved using PMOD software with the simplified reference tissue model 2. Hemi-PD rats exhibited a constant increase of 23% in D2/D3R availability in the CPu, which was almost normalized by intrastriatal application of BoNT-A. Importantly, the BoNT-A effect on striatal D2/D3R significantly correlated with behavioral results in the apomorphine rotation test. Our results suggest a therapeutic effect of BoNT-A on the impaired motor behavior of hemi-PD rats by reducing interhemispheric changes of striatal D2/D3R.

• Publication year

  2018

• Venue

  Molecules

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/molecules23030587PMID 29509680PMCID 6017015
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Levodopa: A new look at an old friend

  2018cited by this paper
• Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

  2018cited by this paper
• Dopamine, Noradrenaline and Serotonin Receptor Densities in the Striatum of Hemiparkinsonian Rats following Botulinum Neurotoxin-A Injection.

  2018cited by this paper
• Intrastriatal administration of botulinum neurotoxin A normalizes striatal D2R binding and reduces striatal D1R binding in male hemiparkinsonian rats

  2018cited by this paper
• Intrastriatal administration of botulinum neurotoxin A normalizes striatal D2R binding and reduces striatal D1R binding in male hemiparkinsonian rats

  2018cited by this paper
• Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico‐basal ganglia loop circuit in vivo in experimental parkinsonism

  2017cited by this paper
• Intrastriatally injected botulinum neurotoxin-A differently effects cholinergic and dopaminergic fibers in C57BL/6 mice.

  2017cited by this paper
• Altered adenosine 2A and dopamine D2 receptor availability in the 6‐hydroxydopamine‐treated rats with and without levodopa‐induced dyskinesia

  2017cited by this paper
• Parkinson’s Disease: From Pathogenesis to Pharmacogenomics

  2017cited by this paper
• Intrastriatal injection of botulinum neurotoxin-A is not cytotoxic in rat brain - A histological and stereological analysis.

  2016cited by this paper
• Correction: A Standardized Method for the Construction of Tracer Specific PET and SPECT Rat Brain Templates: Validation and Implementation of a Toolbox

  2015cited by this paper
• Dopamine D3 receptor binding of 18F‐fallypride: Evaluation using in vitro and in vivo PET imaging studies

  2015cited by this paper
• Expression of human mitochondrial transcriptional factor A (hTFAM) improves cognitive function in Alzheimer?s disease model mice

  2014cited by this paper
• Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory.

  2014cited by this paper
• he effects of unilateral 6-OHDA lesion in medial forebrain bundle on he motor , cognitive dysfunctions and vulnerability of different triatal interneuron types in rats

  2014cited by this paper
• Intracerebrally applied botulinum neurotoxin in experimental neuroscience.

  2013cited by this paper
• Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease

  2013cited by this paper
• Effects of intrastriatal botulinum neurotoxin A on the behavior of Wistar rats.

  2012cited by this paper
• Persistent region-dependent neuroinflammation, NMDA receptor loss and atrophy in an animal model of penetrating brain injury.

  2012cited by this paper
• Updates in the medical management of Parkinson disease

  2012cited by this paper
• Muscarinic modulation of striatal function and circuitry.

  2012cited by this paper
• Neurotoxin-based models of Parkinson's disease.

  2012cited by this paper
• Evaluation of dopamine transporters and D2 receptors in hemiparkinsonian rat brains in vivo using consecutive PET scans of [18F]FPCIT and [18F]fallypride.

  2012cited by this paper
• Dynamic changes of striatal dopamine D2 receptor binding at later stages after unilateral lesions of the medial forebrain bundle in Parkinsonian rat models.

  2011cited by this paper
• Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease.

  2011cited by this paper
• Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [18F]fallypride and [18F]desmethoxyfallypride

  2011cited by this paper
• Test–retest variability of [11C]raclopride‐binding potential in nontreatment‐seeking alcoholics

  2011cited by this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cited by this paper
• Novel Ganglioside-mediated Entry of Botulinum Neurotoxin Serotype D into Neurons*

  2011cited by this paper
• Statistical parametric maps of 18F-FDG PET and 3-D autoradiography in the rat brain: a cross-validation study

  2011cited by this paper
• Striatal Muscarinic Receptors Promote Activity Dependence of Dopamine Transmission via Distinct Receptor Subtypes on Cholinergic Interneurons in Ventral versus Dorsal Striatum

  2010cited by this paper
• Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with [18F]fallypride

  2010cited by this paper
• An improved synthesis of dopamine D2/D3 receptor radioligands [11C]fallypride and [18F]fallypride.

  2010cited by this paper
• Clostridial Neurotoxins: Mechanism of SNARE Cleavage and Outlook on Potential Substrate Specificity Reengineering

  2010cited by this paper
• Endogenous competition against binding of [18F]DMFP and [18F]fallypride to dopamine D2/3 receptors in brain of living mouse

  2010cited by this paper
• NEMA NU 2-2007 performance measurements of the Siemens Inveon™ preclinical small animal PET system

  2009cited by this paper
• Performance Evaluation of the Inveon Dedicated PET Preclinical Tomograph Based on the NEMA NU-4 Standards

  2009cited by this paper
• A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism?

  2009cited by this paper
• Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans

  2007cited by this paper
• RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion

  2006cited by this paper
• Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: A comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride

  2006cited by this paper
• Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease

  2006cited by this paper
• Serial microPET measures of the metabolic reaction to a microdialysis probe implant.

  2006influential reference
• Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease.

  2006cited by this paper
• Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats.

  2005cited by this paper
• Asymmetrical changes of dopamine receptors in the striatum after unilateral dopamine depletion.

  2005cited by this paper
• Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET.

  2004cited by this paper
• Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors.

  2003cited by this paper
• Striatal Volume Changes in the Rat Following Long-term Administration of Typical and Atypical Antipsychotic Drugs

  2002cited by this paper
• Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging

  2002influential reference
• Evaluation of Dopamine D-2 Receptor Occupancy by Clozapine, Risperidone, and Haloperidol In Vivo in the Rodent and Nonhuman Primate Brain Using 18F-Fallypride

  2001cited by this paper
• Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum

  2001cited by this paper
• Autoxidation and Neurotoxicity of 6‐Hydroxydopamine in the Presence of Some Antioxidants

  2000cited by this paper
• Temporal changes of dopaminergic and glutamatergic receptors in 6-hydroxydopamine-treated rat brain.

  2000cited by this paper
• Bihemispheric reduction of GABAA receptor binding following focal cortical photothrombotic lesions in the rat brain.

  1998cited by this paper
• Effect of reserpine‐induced depletion of synaptic dopamine on [11C]Raclopride binding to D2‐dopamine receptors in the monkey brain

  1997cited by this paper
• Evaluation of d‐amphetamine effects on the binding of dopamine D‐2 receptor radioligand, 18F‐fallypride in nonhuman primates using positron emission tomography

  1997cited by this paper
• The effect of dopamine D1 receptor stimulation on the up‐regulation of histamine H3‐receptors following destruction of the ascending dopaminergic neurones

  1996cited by this paper
• Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies

  1996cited by this paper
• 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death.

  1995cited by this paper
• Effect of L‐dopa and 6‐hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET

  1995cited by this paper
• Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.

  1995cited by this paper
• Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy.

  1995cited by this paper
• Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats.

  1993cited by this paper
• Dopamine receptors status after unilateral nigral 6-OHDA lesion. Autoradiographic and in situ hybridization study in the rat brain.

  1993cited by this paper
• Localization of dopamine D2 receptor protein in rat brain using polyclonal antibody.

  1992cited by this paper
• D2 dopamine receptor localization on striatonigral neurons.

  1992influential reference
• Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain

  1991cited by this paper
• Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain

  1989cited by this paper
• Localisation and pharmacological characterisation of D-2 dopamine receptors in rat cerebral neocortex and cerebellum using [125I]iodosulpride.

  1985cited by this paper
• A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography

  1984cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• Quantitation in Positron Emission Computed Tomography: 6. Effect of Nonuniform Resolution

  1982cited by this paper
• Dopamine receptor changes following destruction of the nigrostriatal pathway: lack of a relationship to rotational behavior.

  1981cited by this paper
• Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size

  1979cited by this paper
• Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity.

  1977cited by this paper
• Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

  1970cited by this paper
• Direct chemical stimulation of dopaminergic mechanisms in the neostriatum of the rat.

  1969cited by this paper
• 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists

  1957cited by this paper

• Focused Modulation of Brain Activity: A Narrative Review

  2025cites this paper
• Content CN-21-5

  2023cites this paper
• Exploring the Central Mechanisms of Botulinum Toxin in Parkinson’s Disease: A Systematic Review from Animal Models to Human Evidence

  2023influential citation
• Dopamine D2 receptor upregulation in dorsal striatum in the LRRK2-R1441C rat model of early Parkinson’s disease revealed by in vivo PET imaging

  2023cites this paper
• Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5

  2022cites this paper
• Olfactory Bulb D2/D3 Receptor Availability after Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease

  2022cites this paper
• PET imaging in animal models of Parkinson's disease.

  2022cites this paper
• Application of Fluorescence Microscopy and Behavioral Assays to Demonstrating Neuronal Connectomes and Neurotransmitter Systems in C. elegans.

  2021cites this paper
• Application of and Behavioral Assays to Demonstrating Neuronal and Neurotransmitter Systems in C. elegans

  2021cites this paper
• Interlinking potential therapy with botulinum neurotoxin-A and Parkinson's disease

  2020cites this paper
• Acetylcholine Neurotransmitter Receptor Densities in the Striatum of Hemiparkinsonian Rats Following Botulinum Neurotoxin-A Injection

  2018cites this paper
• Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review

  2018cites this paper